[ATTACH] I have posted a multi year chart of ECYT - Endocyte,...

I have posted a multi year chart of ECYT - Endocyte, the license holder for Lu-PSMA-617 (ie the associated treatment in NOX's LuPIN study). It is referenced on page 17.

I didn't do this to draw any direct comparison between the two companies in any way, but just to show what is not an uncommon SP journey for an investigational biotech going through early clinical phases, especially as it gets towards the "pointy end" of things towards the RHS of the chart.

My first biotech investment (also one of my first share purchases) was back in 2001, a pipeline drug developer. Bought in at 7c, sat through a trip to 25c, and back below 10c, before selling out on the next run through the teens soon after. As the story developed and proved itself it, it flew much higher than that and I stopped checking as it approached $1

Let's back Kelly et al to do their thing, and give NOX66 the best chance for success. The SP will take care of itself as we proceed through the clinical stages, and clinical data directs us to market. In that case we will be looking at many multiples of the current SP.

In an nutshell, investing in a biotech won't suit everyone's personality, and we are all going to have our own tolerance for heat taken. Expect sizeable fluctuations with the inherent uncertainty of early stage trials. Things can change quickly (ideally for the better ) when walking through cancer trials with a novel drug supported by promising pre/early clinical data.